Pharma VC Funds

The Silicon Valley Technology Council (SVTC) operates as a key hub for fostering innovation and investment within the tech sector, particularly in the heart of Silicon Valley. With a strong focus on deep technology, SVTC aligns itself with the latest advancements in sectors like AI, quantum computing, and biotechnology. They work closely with tech leaders to address industry needs, supporting developments that can disrupt traditional models and foster significant growth. Their activities are driven by a mission to propel cutting-edge research into scalable businesses, ensuring the region remains a leader in global innovation. SVTC actively supports startups through partnerships and advocacy, emphasizing areas such as sustainability, ethical AI, and cybersecurity. They push for favorable regulatory environments that can accelerate the deployment of technologies like autonomous vehicles and clean energy solutions. By bringing together public and private stakeholders, the council ensures that Silicon Valley's tech ecosystem remains robust and well-connected. Furthermore, SVTC engages in promoting diversity and education, striving to enhance the local talent pool while also advocating for inclusive immigration policies to attract global tech expertise. Their recent initiatives include policy recommendations on AI, boosting funding for scientific research, and creating pathways for sustainable tech innovations. The council remains a pivotal player, providing insights, networking, and advocacy to ensure that Silicon Valley continues to be synonymous with tech entrepreneurship and growth.

10X Capital is a versatile alternative asset management firm headquartered in New York City, specializing in providing institutional investors access to high-growth opportunities across various asset classes. Founded by Hans Thomas and co-headed by David Weisburd, the firm aligns Wall Street with Silicon Valley, focusing on venture capital, private credit, private equity, and real estate investments. 10X Capital’s notable strategies include venture capital investments in high-growth technology companies through private equity and public markets. They also manage SPACs, IPOs, and securitization, leveraging a deep network and robust analytical capabilities to identify and nurture promising startups. The firm has successfully facilitated the growth of several technology-driven businesses, effectively bridging the gap between institutional capital and innovative ventures​. Key team members include Russell Read, Chief Investment Officer, who brings extensive experience from CalPERS and the Alaska Permanent Fund, and Guhan Kandasamy, Chief Data Officer, known for his expertise in credit risk and data management. The team’s diverse background enables 10X Capital to provide comprehensive support and strategic insights to their portfolio companies​​. The firm’s mission is to democratize access to capital markets, ensuring that high-potential ventures receive the necessary funding and support to scale efficiently. This commitment is evident in their broad range of services and their strategic focus on sectors like technology, real estate, and specialty finance

11.2 Capital is an early-stage venture capital firm based in San Francisco, focusing on breakthrough technologies in artificial intelligence, augmented reality/virtual reality (AR/VR), robotics, space, and data-driven health. They have built a diverse portfolio that includes companies such as Bay Labs, Deep Genomics, and Hinge Health. Their investment strategy centers on early-stage technology startups with the potential for significant impact. 11.2 Capital has made 51 investments, with notable exits including Cruise Automation and Kindred AI. They emphasize supporting companies that leverage data at molecular and behavioral levels to innovate in healthcare, such as Apixio and Hindsait, which use data to enhance patient care and reduce costs. The firm is led by a team with deep expertise in technology and investment. Shelley Zhuang, a notable figure in the venture capital world, brings extensive knowledge in cybersecurity and AI. 11.2 Capital's approach involves not only providing capital but also strategic support to help startups scale effectively. Overall, 11.2 Capital is dedicated to fostering innovation in tech-driven sectors, providing both financial backing and strategic partnerships to enable startups to reach their full potential​.

13 Ventures is a U.S.-based venture capital fund specializing in consumer-facing companies that are already generating revenue and are on a strong growth trajectory. The fund is particularly interested in businesses that demonstrate a clear path to profitability, aiming to back scalable models that can quickly capitalize on market opportunities. While their check sizes and deal specifics are not publicized, they focus on later stages, supporting companies in growing their market presence and operational capacity. Startups are encouraged to have a strong product-market fit and be ready for strategic scaling before approaching the fund. The fund emphasizes the importance of introductions, signaling that they prefer startups to come through a trusted network or via direct recommendations. They value concise and well-prepared pitches that highlight key business metrics such as revenue growth and market positioning. The goal is to ensure each company aligns with 13 Ventures' investment thesis, which centers around robust consumer-driven companies poised for significant expansion. 13 Ventures offers more than just capital; they provide hands-on support to help their portfolio companies overcome operational and growth challenges. Their experience and extensive network provide startups with access to critical resources, including mentorship and partnerships that can accelerate growth. Their ideal investments are in companies that have already proven their ability to generate revenue and are ready to scale to the next level, with a firm foundation and potential for profitability. This focus on high-growth consumer markets sets 13 Ventures apart as a key player in helping companies scale effectively.

1517 Fund, co-founded in 2015 by Michael Gibson and Danielle Strachman, is a venture capital firm with a distinctive focus on backing young founders, dropouts, and renegade scientists. The firm is inspired by the spirit of Martin Luther's 1517 Reformation, challenging the conventional education system and supporting innovators working outside traditional academic tracks. 1517 Fund invests in early-stage startups, including those at the R&D/idea phase up to the Seed stage. They are particularly interested in software, hardware with a data play, deep tech/science fiction tech, and biotech. Their initial investments range from $50,000 to $1,000,000, with an average check size of around $400,000 for pre-seed investments. Notable companies in 1517 Fund's portfolio include Luminar, Lambda, Deepgram, and Figma. They have a community-oriented approach, providing grants, investments, and support to a network of hackers, makers, and scientists globally. This community includes events, workshops, and office hours aimed at fostering innovation and advancing the edges of knowledge and science. The fund's co-founders, Michael Gibson and Danielle Strachman, previously worked with Peter Thiel on the Thiel Fellowship, which provided $100k grants to young entrepreneurs, leading to successful ventures like Ethereum and OYO Rooms. This background underscores their commitment to nurturing unconventional talent and groundbreaking ideas.

1kx is a venture capital firm founded in 2018, specializing in early-stage investments with a focus on blockchain technology and decentralized ecosystems. The firm is headquartered in Road Town, British Virgin Islands, with additional offices in Berlin and Amsterdam. 1kx has made notable investments in several high-profile projects within the blockchain and DeFi sectors. Some of their key investments include Qredo, a blockchain network for DeFi applications; Matter Labs, which focuses on blockchain privacy and verifiable computation; and Rarible, an online marketplace for blockchain-based digital art. Other significant investments include Connext, which offers Ethereum-based P2P micro-payment infrastructure, and Gitcoin, a platform for funding open-source software development. The firm's investment strategy emphasizes supporting projects that build critical infrastructure for decentralized ecosystems. They have made 162 investments to date, with a strong presence in the United States, followed by Germany and France. The leadership team at 1kx includes founding partners Christopher Heymann and Lasse Clausen, along with Diana Biggs, who supports portfolio growth with an institutional lens.

2048 Ventures is a venture capital firm founded in 2018 and headquartered in New York, NY. The firm focuses on early-stage investments, particularly in technology-driven startups. They have a strong portfolio with over 120 investments across diverse sectors, including biotechnology, artificial intelligence, health tech, and commercial products. Some notable companies backed by 2048 Ventures include Adaptis Technologies, an AI-powered platform for optimizing the carbon footprint of buildings, and Fathom Optics, which delivers 3D experiences using standard printing technologies. Their investment strategy is to support visionary founders at the earliest stages, often leading pre-seed and seed rounds. 2048 Ventures has shown significant activity, with their portfolio companies collectively raising $591 million and reaching a valuation of $2.6 billion by the end of 2023. They have invested in innovative companies like TwoStep Therapeutics, which specializes in modular peptide technology for targeting solid tumors, and Century Health, which leverages AI to accelerate drug development​.

2150 is a London, Copenhagen, and Berlin-based venture capital firm focused on transforming urban environments through sustainable technology. With a €268 million fund, 2150 invests in companies that address major challenges across the "Urban Stack"—everything from the design and construction of cities to how they are powered and maintained. Their mission is to support groundbreaking startups that can reimagine urban living, while significantly reducing carbon emissions and improving sustainability. 2150 primarily invests in Series A and B stage companies, with check sizes ranging from $1 million to $7 million. Their focus spans climate tech, green solutions, and innovative materials, all aimed at creating smarter, more efficient cities. The firm’s portfolio includes companies like CarbonCure, which injects recycled CO₂ into concrete to reduce its carbon footprint, Normative, a platform that helps businesses track and manage their carbon emissions, and Ampd Energy, which electrifies construction sites to minimize pollution. Beyond financial backing, 2150 takes a hands-on approach, working closely with founders to scale their businesses and maximize impact. The firm’s ultimate goal is to build a portfolio capable of mitigating gigatonnes of CO₂ emissions, comparable to the entire annual output of countries like Germany and France. With strong backing from investors like Novo Holdings and the BMW Foundation, 2150 is positioned as a key player in the future of urban development, driving both commercial success and global sustainability.

2xN is a London-based, quantum-focused venture capital fund co-founded by Lars Fjeldsoe-Nielsen and Niels Nielsen. The firm specializes in early-stage investments, primarily targeting startups in quantum computing and other sectors with transformative potential like mobility, edtech, and marketplaces. Notable investments include quantum heavyweights Quantinuum and Kvantify, as well as StudySmarter, demonstrating its focus on impactful technologies. With a $120 million fund, 2xN typically invests $3 to $5 million in pre-seed to Series A rounds, actively backing companies across Europe and the U.S. The fund's strategy is highly collaborative, often co-investing with prominent VCs like Sequoia and A16Z, favoring founders with a vision for societal impact. Rather than dominating deals, 2xN aims to create network effects and long-term partnerships, making them a hands-on, founder-first investor. The team’s dual expertise—Nielsen’s pioneering work in quantum computing and Fjeldsoe-Nielsen’s background in Silicon Valley—enables them to offer deep, technical guidance while scaling businesses rapidly. Startups are encouraged to approach the fund with disruptive ideas in core sectors like quantum, as 2xN builds its deal flow through a strong network of repeat entrepreneurs and global investors.

37 Angels is an angel investment network founded in 2012, headquartered in New York, NY. The firm is dedicated to closing the gender gap in startup investing by training more women to become angel investors and by investing in high-potential, diverse startups. Each year, 37 Angels evaluates around 2,500 startups and invests in approximately 10, focusing on both male and female-led companies. Their portfolio includes a variety of innovative startups across different sectors. Notable investments include ChalkTalk, an e-learning platform, Partake Foods, a food products company, and EarlyBird, a financial software firm. They also have significant investments in companies like Pulp Pantry, which focuses on sustainable food products, and Sensate, which provides health and wellness solutions. 37 Angels has had multiple successful exits, such as Owlet Baby Care, which went public, and Kinsa Health, which was acquired by a larger firm. Their investment strategy involves supporting startups from early stages through to growth, offering both capital and strategic guidance to help them scale.

3B Ventures is an impact-driven venture capital firm founded in 2017 with headquarters in Copenhagen, Denmark. The fund primarily focuses on solving global challenges through investments in key sectors like agribusiness, clean-tech, energy, and healthcare. It has a global reach, with a particular focus on markets in Malaysia, Europe, and the United States. The firm targets early-stage startups and seed-stage companies that are developing innovative solutions with potential for significant impact. 3B Ventures has been involved in notable investments like AnaCardio, a biopharma company focused on medical advancements, where they participated in a substantial $18 million funding round. The fund’s average deal size is around $18 million, indicating that it takes a substantial approach to backing its portfolio companies. Founded by James Digby and Jan-Cayo Fiebig, 3B Ventures is committed to not only providing capital but also delivering strategic support to help companies scale and solve large-scale global problems. The firm tends to look for entrepreneurs passionate about creating change, with business models that align with their vision for a sustainable and impactful future. They prefer to work with founders who have a clear path to growth and profitability, and they actively engage in nurturing these businesses through their extensive network and resources. Entrepreneurs looking to approach 3B Ventures are encouraged to present well-developed solutions with demonstrable traction in key markets.

3E Bioventures Capital is a prominent venture capital firm specializing in the life sciences sector, focusing on innovative therapeutic drugs and disruptive med-tech. Founded with a mission encapsulated in their name—Expertise, Efficiency, Execution—3E Bioventures actively invests in global health innovators and TechBio, aiming to disrupt conventional paradigms by integrating biology with technology​​. Notable investments include Aravive, which develops biologic drugs targeting tumor metastasis, and C4 Therapeutics, which pioneers small-molecule drugs that degrade disease-causing proteins. Their portfolio also boasts companies like Cytek, which offers a transformative flow cytometry platform, and Twist Bioscience, known for its advanced DNA synthesis technology​​. Geographically, 3E Bioventures operates with a global perspective, maintaining a strong presence in the US and China. They often participate in early-stage and growth-stage investments, providing significant support in both capital and strategic guidance​​. The firm’s team includes experienced professionals such as Li Jing, Frank Yan, and Linda Liu, who leverage their deep industry knowledge to support portfolio companies effectively. They emphasize a science-driven, entrepreneur-friendly approach, working closely with research institutions and companies to address unmet medical needs​. For startups seeking investment, 3E Bioventures looks for breakthrough innovations in biotech and med-tech, focusing on areas with strong medical needs and the potential for significant impact. They prefer to engage with companies that align with their strategic goals and demonstrate a clear pathway to success​​.

3M Ventures, the corporate venture capital arm of 3M, focuses on investing in early-stage companies that align with 3M's strategic priorities. These priorities include automotive electrification, safety, home improvement, consumer electronics, climate tech, sustainable packaging, industrial automation, and semiconductor and data center technologies. Their investment strategy targets companies with strong intellectual property, demonstrated commercial traction, and robust management teams​. Notable investments by 3M Ventures include GrayMatter Robotics, Moxe Health, and Metalenz, which span across artificial intelligence, healthcare, and 3D technology, respectively. 3M Ventures seeks to not only provide financial investment but also leverage 3M's extensive technological platforms, manufacturing capabilities, and global networks to help scale their partner companies​. 3M is also heavily committed to sustainability. The company has pledged $1 billion to achieve carbon neutrality, reduce water use, and improve water quality by 2030. This initiative includes implementing state-of-the-art water purification technology and developing innovative solutions for renewable energy and emissions reduction​.

3x5 Partners is a Portland, Oregon-based venture capital firm that focuses on investments in companies developing solutions for global health and climate challenges. Founded in 2011 by Tony Arnerich and Nicholas Walrod, the firm has raised over $400 million across multiple funds, including their most recent $100 million Fund III. 3x5 Partners primarily invests in late-stage (Series A/B) ventures within sectors such as biotechnology, medical devices, diagnostics, and clean technology. The firm is known for its commitment to long-term partnerships, often leading early investment rounds and providing significant follow-on funding. Notable investments include companies like Fervo Energy, Arch Oncology, and Smart Wires, all of which align with their mission to create meaningful social and environmental impact. 3x5 Partners differentiates itself by focusing on capital-intensive, high-impact ventures that are often overlooked by traditional venture capital firms. They take an active role in the companies they invest in, serving as board members and strategic partners to guide these ventures through critical growth stages. The firm's leadership team, which includes seasoned investors like Joe Biller and David Yeh, is deeply experienced in both impact investing and venture capital, ensuring that they not only generate strong returns for their investors but also contribute to solving some of the world's most pressing problems.

42CAP, established in 2016 and based in Munich, Germany, is a venture capital firm that focuses on seed-stage investments in B2B technology startups across Europe. The firm is notable for its emphasis on data-driven and SaaS companies, with a strong interest in applications of artificial intelligence and machine learning. Their portfolio includes notable startups like Adverity, a marketing analytics platform, and OnTruck, a real-time marketplace for truck deliveries. 42CAP typically invests between €0.5 million and €1.5 million per company and aims to back ventures that can scale globally from a European base. 42CAP's strategic approach involves partnering with visionary founders to drive technological innovations in B2B sectors. They seek companies that enable organizational agility and efficiency, particularly in fields such as big data and IoT. Their latest fund, totaling €50 million, is set to support approximately 20 startups, expanding on the success of their initial investments. The team behind 42CAP includes experienced entrepreneurs and investors like Alex Meyer and Thomas Wilke, who previously built successful companies such as eCircle and Relayr. This diverse and experienced team is integral to their hands-on approach in supporting portfolio companies from early stages to market leadership.

4BIO Capital is a London-based venture capital firm specializing in advanced therapies, particularly in areas like gene therapy, cell therapy, RNA-based treatments, and the microbiome. The firm is focused on addressing high unmet medical and social needs through early-stage investments in innovative life sciences companies. Founded by a team of experienced academics, physician-scientists, and industry executives, 4BIO Capital has built a strong reputation for its deep expertise in the rapidly evolving field of advanced therapies. The firm’s strategy involves not only backing early-stage startups but also creating new companies by leveraging cutting-edge research from academic institutions across Europe and the U.K. 4BIO Capital recently raised $50 million for its second advanced therapy VC fund, with plans to increase this to $150 million. This fund is dedicated to expanding the use of advanced therapies beyond rare diseases to treat more prevalent conditions like diabetes and rheumatoid arthritis. The firm has a global investment focus, with no geographical restrictions, though it emphasizes the untapped potential within U.K. institutions. The team at 4BIO includes managing partners Dmitry Kuzmin and Andrew Kozlov, who bring a wealth of knowledge and experience in life sciences and venture investing, helping to drive the firm’s mission of bringing transformative therapies to market​.

4DX Ventures is a prominent venture capital firm dedicated to fostering technological innovation across Africa. Established in 2014, the firm focuses on early to growth-stage investments in diverse sectors, including fintech, e-commerce, healthtech, climate tech, edtech, and logistics. Noteworthy portfolio companies include Andela, Flutterwave, and mPharma, showcasing their commitment to supporting transformative startups on the continent. Geographically, 4DX Ventures has a strong presence in key African markets with offices in Accra, Cairo, and Nairobi. This regional focus allows them to provide robust support and leverage local insights effectively. Their investment strategy is characterized by a deep commitment to partnering with visionary entrepreneurs. They emphasize rigorous due diligence and provide strategic, operational, and technical support to help startups scale. The firm typically leads investment rounds, ensuring substantial backing and ongoing guidance. 4DX Ventures was co-founded by Peter Orth, Walter Baddoo, Daniel Marlo, and Raaid Ahmad, who collectively bring a wealth of experience from prestigious institutions like Morgan Stanley and Bridgewater Associates. The team is dedicated to maintaining high standards of integrity, transparency, and excellence in all their endeavors. Recently, 4DX secured a $10.5 million investment from the International Finance Corporation (IFC) for their third pan-African fund, further solidifying their capacity to drive impactful investments across the continent. Startups are encouraged to approach 4DX with innovative solutions that have the potential for significant impact and scalability.

Founded in 2012, 50 Partners is a Paris-based venture capital firm and startup accelerator. It stands out for its robust support of early-stage companies in the tech, impact, and healthtech sectors. Notable investments include Pixacare, Surge, Wakeo, and Albert. They have achieved successful exits with companies like SimpliField, ProcessOut, and TwicPics. 50 Partners primarily focuses on the French market but has also shown interest in broader European opportunities. Their investment strategy emphasizes early-stage funding, with an average round size of around $2 million. They typically make about seven investments per year and have been particularly active recently, with peak activity in 2022. The team at 50 Partners consists of experienced entrepreneurs and investors, including co-founders Jérôme Masurel, Christophe Berly, Laurent Letourmy, and Rolland Mor. These leaders bring diverse expertise across various industries and business models, providing valuable mentorship to their portfolio companies. For startups looking to engage with 50 Partners, it's crucial to demonstrate strong innovation and scalability potential. They prefer to work closely with founders who are transparent and collaborative, ensuring a good fit with their hands-on approach to nurturing growth.

500 Global, formerly known as 500 Startups, is a prominent venture capital firm with a robust global presence and over $2.4 billion in assets under management. Since its inception in 2010, it has invested in more than 2,800 companies across 80+ countries. Some of its most notable investments include Credit Karma, Twilio, Canva, Grab, Bukalapak, The RealReal, Talkdesk, Udemy, and Ipsy​​. 500 Global's industry focus spans various sectors, with significant investments in consumer services, software-as-a-service (SaaS), fintech, and media​ (Proptech Zone)​. Its geographic focus is truly global, with operations in major innovation hubs such as Silicon Valley, New York, London, Singapore, and Mexico City, as well as emerging markets like Lagos, Jakarta, and Riyadh​​. The fund's strategy involves early-stage investments, providing seed capital along with comprehensive support through its Seed Accelerator Programs. These programs emphasize digital marketing, customer acquisition, lean startup methodologies, and fundraising strategies. 500 Global prefers to invest in companies with high growth potential and innovative business models​. Typically, 500 Global invests an average of $150,000 to $250,000 in initial seed rounds and often leads these rounds. The firm is known for its hands-on approach, leveraging its extensive network of mentors, industry experts, and alumni to support portfolio companies. Recently, 500 Global has been active in launching thematic funds targeting specific industries and regions, further expanding its investment reach​​. The leadership team includes Christine Tsai, the CEO and Founding Partner, who has steered the firm’s growth and global expansion. 500 Global's diverse team of over 100 members spans more than 30 countries, bringing a wealth of experience as entrepreneurs, investors, and operators from leading tech companies​.

574 Invest is the corporate venture capital arm of the SNCF Group, France’s national railway company. Established in 2019 and headquartered in Paris, the fund focuses on early to growth-stage investments in sectors like mobility, Industry 4.0, and climate tech. The fund’s primary mission is to drive innovation in the transportation and industrial sectors, aligning with SNCF’s broader objectives of enhancing sustainable mobility solutions. 574 Invest mainly targets investments in France and Europe, seeking companies that are pioneering new technologies in areas such as micro-mobility, mass transit, and green mobility. The fund leverages SNCF’s extensive industry expertise and resources to offer more than just capital, providing strategic partnerships and access to the company’s vast commercial network. This allows portfolio companies to collaborate closely with SNCF’s various business units, accelerating the development and adoption of their technologies. Some of 574 Invest's notable investments include Electra, which focuses on energy services, and XXII, a company specializing in computer vision technologies. The fund also actively promotes the integration of Industry 4.0 technologies, such as IoT and predictive maintenance, within the transportation sector. 574 Invest's approach is highly strategic, aiming to foster long-term partnerships that can enhance both the SNCF Group's operations and the broader mobility ecosystem.

5AM Ventures, established in 2002, is a prominent venture capital firm specializing in early-stage investments in life sciences. They have a significant presence in both San Francisco and Boston. The firm focuses on biopharmaceuticals, drug delivery technologies, and life science instruments. Their portfolio includes notable companies like Envoy, Epirus, Flexion, Homology Medicines, and Ideaya Biosciences, showcasing their broad impact across the healthcare sector. 5AM Ventures adopts a hands-on approach through their 4:59 Initiative, partnering with academics and entrepreneurs to incubate breakthrough science. They provide both venture capital for private therapeutic companies and public equity investments in small and mid-cap biotech firms. This strategy allows them to support companies from inception through to later stages of development and public offerings. Geographically, 5AM Ventures focuses on investments within the United States, fostering innovation in healthcare by backing companies that address critical medical needs through cutting-edge technology. Their recent exits include companies like Escient Pharmaceuticals and Impel Neuropharma, demonstrating their successful track record. The team at 5AM Ventures includes co-founders Andrew Schwab and John Diekman, along with managing partner Kush Parmar. Their combined expertise in science, medicine, and finance positions them as key players in shaping the future of life sciences. For startups looking to partner with a venture capital firm that offers deep industry knowledge and a robust network, 5AM Ventures presents a compelling opportunity to advance healthcare innovation.

645 Ventures, founded in 2014 and based in New York City, is an early-stage venture capital firm known for backing high-growth technology startups. The firm has a strong focus on sectors such as SaaS, digital health, e-commerce, and data infrastructure. Their portfolio includes notable companies like FiscalNote, a platform that helps organizations navigate legislation; Iterable, a cross-channel marketing platform; and Goldbelly, a food delivery service that specializes in regional delicacies. 645 Ventures invests in startups that leverage data to enhance customer experiences, transform traditional industries through software, and innovate within the engineering value chain. They are particularly interested in the second wave of SaaS applications, which address the evolving needs of distributed workforces and the adoption of technology in new business areas. The firm is co-founded by Nnamdi Okike and Aaron Holiday, who bring extensive experience and a hands-on approach to supporting their portfolio companies. This includes helping with customer acquisition, talent recruitment, and fundraising strategy. With a geographic focus primarily in the United States, 645 Ventures also maintains a presence in San Francisco to tap into the West Coast's innovation ecosystem. Their investments range from seed to Series B stages, and they actively lead rounds and provide follow-on funding.

7percent Ventures is a London-based venture capital firm founded in 2014 by ex-founders Andrew Scott and Andrew Gault. Specializing in early-stage investments, the firm focuses on deep-tech startups with transformative potential, often referred to as "moonshot" companies. 7percent Ventures targets industries such as AI, quantum computing, AR/VR, spacetech, and future computing. Their investment philosophy is driven by supporting highly ambitious projects that aim to disrupt entire industries. The firm typically invests at pre-seed, seed, and Series A stages, with a typical investment range of €100,000 to €1.5 million. Notable companies in their portfolio include Oculus VR, which was acquired by Meta, and Universal Quantum, a pioneer in quantum computing. They also have a strong transatlantic reach, with investments spanning both the U.K. and the U.S., particularly in Silicon Valley. 7percent Ventures’ partners bring over 150 years of combined experience as entrepreneurs and investors, offering not just capital but also strategic mentorship, leveraging their extensive networks to help startups scale. The firm emphasizes the importance of transformative innovation and risk-taking in achieving sector-defining success​.

7wireVentures, co-founded by Glen Tullman and Lee Shapiro, is a venture capital firm that invests in early-stage digital health companies. The firm focuses on empowering consumers with innovative health solutions and technologies. Notable investments from 7wireVentures include Livongo, a chronic care management company that was acquired by Teladoc in a significant $18.5 billion deal, and NOCD, which focuses on providing virtual therapy for obsessive-compulsive disorder. Other prominent portfolio companies include FOLX Health, which offers virtual healthcare for the LGBTQIA+ community, and Brightline, a tech-enabled behavioral health platform for children and families. Recently, 7wireVentures closed a $217 million Growth & Opportunity Fund to support their existing portfolio and invest in Series B and C companies. This new fund brings their total assets under management to over $500 million. The firm continues to focus on "consumer-first, tech-enabled health and care solutions," reflecting their commitment to driving the digital transformation of healthcare.

8VC is a dynamic venture capital firm that focuses on investing in cutting-edge technology and life sciences startups. Notable investments in their portfolio include industry leaders such as Flexport, Guardant Health, Joby Aviation, and Palantir. 8VC primarily targets sectors like healthcare, logistics, IT infrastructure, and defense, with a strong emphasis on transformative technologies that drive significant societal impact. Geographically, 8VC invests globally but has a particular focus on the United States. The firm's investment strategy is centered on early-stage companies, often leading funding rounds with check sizes ranging from $100K to $50M. 8VC is known for its hands-on approach, supporting entrepreneurs not just with capital, but also with deep operational expertise and a robust network. They actively participate in the development of their portfolio companies, sometimes even building companies from the ground up when necessary. Led by Joe Lonsdale, a co-founder of Palantir, 8VC's team includes seasoned professionals with diverse backgrounds in technology, finance, and entrepreneurship. The team operates out of multiple locations, including San Francisco and Austin, positioning them at the heart of the innovation ecosystem. Startups looking to engage with 8VC should be prepared to demonstrate a strong potential for societal impact and innovative technology solutions. The firm values direct, compelling pitches and prefers to be approached through warm introductions within their extensive network.

9Yards Capital is a San Francisco-based global investment firm focused on growth-stage technology companies, particularly in fintech and logistics. With a strategic emphasis on companies that leverage technology to transform foundational industries, the firm aims to be more than just financial backers. They provide deep industry expertise, particularly in regulatory frameworks, which allows them to offer unique value to their portfolio companies. This includes high-profile investments like Robinhood, Coinbase, Better, and Toast, among others. 9Yards operates across both the U.S. and Europe, targeting investments from early-stage ventures to Series B+ rounds. They typically invest between $100,000 to $10 million, depending on the company's stage and needs. Known for its patient, long-term approach, the firm ensures that its portfolio companies have the resources and connections needed to scale efficiently, often co-investing with other major players in the venture capital landscape. The leadership at 9Yards includes prominent figures such as David Fisher and George Osborne, who bring strong financial and operational expertise. Their team also benefits from the guidance of strategic advisers like Malcolm Turnbull and Admiral Mike Rogers, adding a diverse and influential network that strengthens their ability to impact industries globally. With over $800 million in assets under management, 9Yards Capital continues to be a significant player in shaping the future of technology-driven industries

A-Star is a dynamic investment firm that excels in scaling early-stage companies with significant growth potential. The firm’s strategy revolves around providing both capital and strategic support, ensuring that startups can transition from promising ideas to thriving businesses. A-Star is deeply committed to fostering long-term partnerships, taking a hands-on approach in guiding companies through critical growth stages. The firm’s team boasts a wealth of experience in entrepreneurship, finance, and venture capital, enabling them to identify and nurture innovative businesses across a wide range of sectors. This expertise allows A-Star to build a diverse portfolio of transformative companies, each poised to make a substantial impact in their respective industries. With a keen focus on sustainable growth and long-term success, A-Star partners with entrepreneurs who share a vision for innovation and excellence. Through their dedicated involvement, A-Star helps these companies navigate the complexities of scaling, providing the necessary tools and resources to achieve market leadership. The firm’s approach is characterized by its emphasis on collaboration and its commitment to the sustained success of its portfolio companies. By leveraging their extensive network and industry insights, A-Star not only supports the growth of individual companies but also contributes to the broader entrepreneurial ecosystem. Their mission is to empower visionary founders and turn high-potential startups into market-leading enterprises, driving meaningful change and creating lasting value.

AAF Management Ltd., founded in 2016 and headquartered in Washington, D.C., is a prominent early-stage venture capital firm. The firm focuses on pre-seed, seed, and Series A stage technology companies in North America, with particular emphasis on sectors such as fintech, healthcare, consumer tech, enterprise software, and deep tech. AAF Management has an impressive portfolio of over 120 venture-backed companies. Notable investments include Robinhood, Didi, Savage X Fenty, StockX, Figure, Reddit, Current, Synthego, Jasper, and Drata. The firm has also celebrated significant exits, such as CrowdStrike (NASDAQ: CRWD), TruOptik (acquired by TransUnion), Even Financial (acquired by MoneyLion), Prodigy (acquired by Upstart), Portfolium (acquired by Instructure), and HeyDoctor (acquired by GoodRx). The firm is backed by over 95 limited partners, including family offices, royal families, C-level executives, and hedge fund managers from the US, Europe, and MENA regions. AAF Management prides itself on its strategic value-add, leveraging a vast network to support its portfolio companies and emerging managers globally.

ABB is a global leader in electrification, automation, robotics, and motion technologies, aiming to drive sustainable industrial transformations. Headquartered in Switzerland, ABB operates in over 100 countries and employs around 105,000 people. Their solutions focus on increasing energy efficiency and improving productivity across a wide range of industries, from utilities and transport to infrastructure and manufacturing. ABB’s business is organized into four key areas: Electrification, Motion, Robotics & Discrete Automation, and Process Automation. These divisions help industries across the globe innovate and optimize their processes. For example, ABB's Robotics division is one of the world’s leading providers of robotics and machine automation solutions, integrating advanced technologies like AI and the Internet of Things (IoT) to support smarter factories. In addition to their core business, ABB is deeply involved in sustainability efforts. They are committed to reducing carbon emissions and supporting the transition to renewable energy, as seen in their contributions to electric vehicle (EV) infrastructure and sustainable transport solutions. ABB has partnered with organizations such as NASCAR to explore electrification in motorsports, furthering innovation in high-performance electric racing vehicles. The company’s strong focus on research and development has led to cutting-edge innovations, particularly in electrification, where they design energy-efficient solutions to power cities and industries sustainably. ABB's global footprint and long-standing commitment to innovation make them a key player in driving the future of industrial automation and clean energy.

Abies Ventures is a Tokyo-based venture capital firm that specializes in deep tech investments, aiming to tackle global issues like environmental degradation and food shortages through science and advanced technologies. Established in 2017, the firm focuses on early-stage companies with innovative solutions in areas such as AI, robotics, quantum computing, and biotech. Their portfolio includes cutting-edge startups like Synspective, Telexistence, and Mighty Buildings, reflecting their commitment to building sustainable, tech-driven solutions. Abies Ventures leverages its strong global network, partnering with large corporations, research institutes, and government agencies to help startups scale internationally. The fund is led by experienced venture founders like Fuyuki Yamaguchi and Sota Nagano, who bring extensive expertise in venture investment and scaling companies across Japan and the U.S. Their investment strategy centers on fostering deep tech companies with high impact potential, particularly in areas where finance, technology, and market dynamics may not always align. Abies Ventures helps bridge these gaps by providing strategic advice and connecting startups with key players to enhance their growth trajectory​.

Abingworth, founded in 1973, is a transatlantic life sciences investment firm with a robust portfolio and a strategic focus on turning innovative science into transformative medical treatments. With offices in London, Boston, and San Francisco, Abingworth has invested in over 179 companies, resulting in 73 IPOs and 46 M&As. The firm operates across three main investment stages: seed and early-stage, development stage, and clinical co-development, and typically invests between $500,000 to $2 million in initial rounds, supporting portfolio companies through subsequent funding stages. Notable investments include Adaptate Biotherapeutics, Jasper, and Tizona Therapeutics. Abingworth's team, led by Managing Partners Tim Haines and Kurt von Emster, brings decades of experience in life sciences and venture capital. The firm is deeply embedded in key biotech hubs, facilitating productive interactions with entrepreneurs and access to top-tier scientific talent. The firm emphasizes long-term partnerships, providing not just capital but also strategic guidance in areas such as clinical development, regulatory approval, and commercialization. Abingworth's recent integration with Carlyle Group underscores its commitment to expanding its impact in the global healthcare investment ecosystem. Startups seeking investment from Abingworth should have groundbreaking science with the potential to materially improve patient outcomes. The firm values deep industry expertise, strong leadership, and a clear path to transformative impact.

Able Partners, founded in 2016 and based in New York City, is a venture capital firm that focuses on investing in early-stage companies aiming to improve daily lives through health and wellness. The firm is known for its support of passionate entrepreneurs and inspiring brands across various industries including consumer products, health tech, and wellness. Their diverse portfolio includes investments in companies such as Clare, a direct-to-consumer paint company; Alto Neuroscience, a company focused on precision psychiatry; Little Otter, a mental health service for children and families; and Kindred, a network for professional caregivers. Other notable investments are Beam Impact, Vivvi, and Capable Health. Able Partners has made over 60 investments and has achieved multiple successful exits. Key exits include Alto Neuroscience, Stretch*d, and Capable Health, showcasing their ability to support companies from early stages to successful outcomes. The firm is led by co-founders Lisa Blau and Amanda Eilian, who bring extensive experience in consumer-focused investments and entrepreneurship. Their investment strategy emphasizes not only providing capital but also leveraging their extensive networks and expertise to help portfolio companies achieve their full potential.

Abstract Ventures is a San Francisco-based VC firm founded in 2016, focusing on early-stage investments across biotech, consumer products, crypto, and enterprise frontier tech. The firm has gained a reputation for backing innovative and high-potential startups, with a portfolio that includes successes like Rippling and Material, the latter achieving unicorn status in 2022. Abstract Ventures primarily targets investments within the U.S., engaging in Seed and Series A rounds with typical check sizes ranging from $5 to $15 million. Their strategy blends flexibility with strategic partnerships, often co-investing with other VCs and leading rounds when they see transformative potential. Abstract is known for being founder-friendly, offering not just capital but also access to a wide network of industry experts, experienced entrepreneurs, and investors who can provide significant strategic value. In 2024, Abstract maintained a proactive stance, completing 16 new investments in companies such as Unify and Thirddimension.ai. The firm’s small yet powerful team is spearheaded by founder and General Partner Ramtin Naimi, who, along with four other partners, leverages years of investment experience and market insight from their base in San Francisco. Abstract Ventures advises founders to approach with a robust market strategy, proven product traction, and genuine storytelling. Rather than solely evaluating polished decks, the firm seeks authenticity and conviction in a startup’s vision. They primarily source deals through referrals and their network, emphasizing relationships and strategic alignment. With this approach, Abstract has carved out a distinctive presence in the early-stage VC landscape, empowering founders from idea to growth phase.

AC Ventures (ACV) is a prominent venture capital firm focused on early-stage technology investments in Indonesia and Southeast Asia. Since its formation in 2019, the firm has built a robust portfolio of over 120 startups, including notable names like Xendit, Carsome, and Ula. ACV's industry focus spans fintech, logistics, e-commerce, and consumer technology, with an emerging interest in climate tech. Geographically, ACV targets Indonesia and the broader Southeast Asian market. The firm’s investment strategy is early-stage centric, often being the first institutional investor in startups. They typically invest $2 million per company, reserving a significant portion for follow-on investments. ACV’s approach is deeply thematic and research-driven, focusing on scalable business models and market comparability to make quick, informed decisions. ACV’s team is led by experienced investors, including co-founders Michael Soerijadji and Adrian Li, and managing partner Helen Wong. The team is based primarily in Indonesia but also has offices in Singapore and Malaysia. Their leadership is known for its diversity, with 50% of senior roles filled by women. The fund is known for its hands-on value creation, providing startups with extensive support in business development, strategic partnerships, talent acquisition, and compliance. ACV’s recent Fund V, targeting $250 million, underscores its commitment to driving economic and societal impact through technology investments in the region​.

Accel is a renowned venture capital firm known for its strategic investments across various stages and sectors. Founded in 1983, Accel has played a pivotal role in the success of numerous high-profile companies. Some of its most notable investments include Facebook, Dropbox, Spotify, and Slack, showcasing its strength in identifying and backing transformative technology companies early on. The firm's investment strategy focuses on seed and Series A funding, ensuring deep engagement with startups from their inception. Accel emphasizes a collaborative approach, providing not just capital but also mentorship and strategic support to help entrepreneurs build market-defining businesses. This hands-on involvement has led Accel to lead investments in over 70% of its portfolio companies​. Accel operates globally, with key offices in Silicon Valley, London, and Bangalore, enabling it to tap into entrepreneurial talent worldwide. The firm has recently closed on several funds totaling $3.05 billion, aimed at supporting early-stage startups and growth rounds for more mature companies​​. In 2023, Accel made significant investments in companies like Blackpoint Cyber, Headway, and Cyera, reflecting its commitment to diverse sectors such as cybersecurity, mental health, and data protection​​. This broad sector focus, combined with a global investment perspective, positions Accel as a key player in the venture capital landscape, continuously driving innovation and supporting exceptional entrepreneurs around the world.

Accelerace is one of the most prominent pre-seed investors and startup accelerators in the Nordics, headquartered in Copenhagen. Founded in 2008, it has supported over 700 startups, including high-profile companies like Trustpilot, Templafy, and Coinify. Accelerace focuses on providing early-stage startups with capital and mentorship, investing up to 1 million DKK through standardized convertible loans. Their investment strategy targets industries such as fintech, healthtech, climatetech, SaaS, and e-commerce, helping startups build scalable solutions across these sectors. The firm’s accelerator program is a comprehensive seven-week initiative designed to prepare startups for fundraising, offering support with pitching, business development, and investor connections. Startups that graduate from the program gain access to the Accelerace Allstars community, a lifelong network of successful founders and industry experts who provide ongoing mentorship and strategic advice. Notable alumni include Donkey Republic and Actimo, which both achieved successful exits. With over 600 investments and a solid presence in Denmark, the Baltics, and other European regions, Accelerace continues to play a pivotal role in shaping the future of innovation in Europe.

Accelerated Ventures, based in San Mateo, California, is a venture capital firm focused on early-stage investments in tech and life sciences. The firm has built a diverse portfolio that includes notable companies such as Telesentry, Amnesty, and Diag-X. Their investment strategy emphasizes sectors like HealthTech and retail, aiming to support innovative startups in these industries. With a portfolio count of six companies, Accelerated Ventures provides funding and strategic guidance to help these startups scale and succeed. Key investments like Telesentry and Diag-X highlight their commitment to fostering growth in tech and healthcare. The firm is led by experienced professionals who bring a wealth of knowledge and expertise to their investment approach, ensuring that each portfolio company receives the support needed to thrive in competitive markets.

Accion Venture Lab is an early-stage venture fund focused on empowering inclusive fintech startups that serve underserved and low-income populations globally. Established as part of Accion, a nonprofit dedicated to financial inclusion, Venture Lab provides seed-first capital paired with extensive strategic and operational support to help startups scale and overcome early challenges. Their diverse portfolio features innovative companies like Apollo Agriculture, which offers tech-driven financing to smallholder farmers in Kenya and Zambia, and Bababos, an Indonesian platform that supports small-scale manufacturers with raw materials and financing solutions. With a geographic reach that spans Latin America, the Caribbean, sub-Saharan Africa, the Middle East, North Africa, Southeast Asia, and even parts of the U.S., Accion Venture Lab's commitment is global. The fund targets industries such as digital lending, insurtech, personal financial management, and MSME-focused solutions, identifying startups with a mission to address systemic barriers to financial access. Their strategy is unique in that they prefer being the first institutional investor, ensuring startups receive not just capital but high-touch mentorship and strategic guidance. In 2019, Accion Venture Lab boosted its support efforts by launching a $23 million fund aimed at deepening their investment into inclusive fintech. Their approach prioritizes not only financial backing but also leveraging their deep-rooted expertise in financial inclusion to provide hands-on operational assistance. The team is led by seasoned Managing Partners Amee Parbhoo and Rahil Rangwala, who bring years of experience in fintech, impact investing, and scaling social enterprises. Founders looking for support from Venture Lab should demonstrate impactful, scalable solutions with clear pathways to financial inclusion.

Accomplice Ventures, founded in 2015 and based in Boston, Massachusetts, is a prominent seed-led venture capital firm. The firm specializes in technology startups across various sectors including cybersecurity, eSports, data analytics, SMB software, emerging hardware platforms, and marketplaces. Notable investments by Accomplice include leading tech companies such as DraftKings, AngelList, Carbon Black, CoinList, Currencycloud, and FreshBooks. Their portfolio also features innovative firms like Hopper, Patreon, PillPack, SecurityScorecard, Veracode, and WHOOP. Accomplice has a significant track record of successful exits, with companies like Datadog, Snap, and DraftKings achieving substantial market presence and growth. Accomplice operates with a unique federated VC model, supporting initiatives such as the operator-angel movement through Spearhead and the blockchain sector via Accomplice Blockchain. They are also anchor LPs in numerous solo GP funds, reflecting their commitment to a diverse and dynamic investment strategy. The firm was initially part of Atlas Venture before the tech and life sciences groups split, with Accomplice focusing solely on tech investments. They have raised multiple funds, including $405 million for their final fund as of 2022, ensuring a robust financial backing for their portfolio companies. Accomplice's investment philosophy is centered on being high conviction, concentrated, and patient investors, dedicated to helping founders build successful, market-leading companies​.

ACME Capital is a prominent venture capital firm based in San Francisco, specializing in early-stage investments in disruptive technologies and innovative business models. Founded in 2013 by Hany Nada, Shervin Pishevar, and Scott Stanford, the firm focuses on sectors such as healthcare, financial services, and space exploration. Their notable investments include high-profile companies like Uber, Slack, and DraftKings, demonstrating a knack for identifying and nurturing industry leaders. ACME Capital's investment strategy is centered on supporting visionary founders who are tackling large-scale challenges with groundbreaking solutions. They emphasize platform shifts and technology breakthroughs that promise significant societal benefits. The firm typically leads funding rounds and provides not just capital, but also strategic guidance and operational support to help startups scale effectively. Geographically, ACME Capital has a strong focus on the United States, but their portfolio also includes companies with a global reach. Their commitment to diversity and inclusion is reflected in their investment choices, with a significant portion of their portfolio companies led by underrepresented founders. The team at ACME Capital includes experienced partners like Brian Yee and Alexander Fayette, who bring a wealth of expertise and a hands-on approach to their investment process. Entrepreneurs looking to engage with ACME Capital are encouraged to present bold, transformative ideas that have the potential to disrupt massive markets and drive significant impact.

ACME Capital, founded in 2018 and headquartered in San Francisco, is an early-stage venture capital firm specializing in transformative technologies and business model innovations. They invest in deep tech, hardware, disruptive consumer products, enterprise solutions, fintech, health, and web3 sectors. Notable portfolio companies include IonQ, Braintrust, Cue Health, Astra, Uhnder, and Forte, which exemplify ACME’s commitment to pioneering advancements and societal benefits. ACME's strategy emphasizes partnering with founders from ideation through to IPO, offering not just capital but also strategic support and valuable industry connections. They favor investments in companies demonstrating significant market traction and a clear path to scalability. Their recent Fund IV and adjacent Opportunity Fund raised over $300 million, underscoring their robust position in the venture capital landscape. ACME is also dedicated to diversity and inclusion, with a substantial portion of their investments and team members representing historically underrepresented groups. Key team members include Co-founders Hany Nada and Scott Stanford, who bring extensive experience in venture capital and entrepreneurship, enhancing ACME’s ability to guide startups toward successful exits.

Acorn Pacific Ventures, founded in 2015, is a venture capital firm based in San Mateo, California. The firm focuses on early and growth-stage technology companies, with a particular emphasis on cross-border investments between the U.S. and Asia. Their portfolio spans industries like e-commerce, AI, fintech, and healthcare, including notable investments in Reap, a Hong Kong-based fintech company, and PopChill, an e-commerce fashion platform. Acorn Pacific is known for its strategic expertise in cross-border expansion, helping startups navigate both Silicon Valley and Asia-Pacific markets. The firm targets companies that leverage proprietary technology and tackle complex challenges in Industry 4.0 and global supply chain transformation. Their typical investment range varies, but they are active in funding rounds from seed to Series B. Led by Chih-Kai Cheng and a team of experienced partners, Acorn Pacific provides not only capital but also operational support to help companies scale. Their portfolio includes ventures like Nuohui Health, Avatar Medical, and Proglix, demonstrating their strong presence across various tech-driven sectors​.

Acre Venture Partners, founded in 2016 and based in Santa Monica, California, is a venture capital firm focusing on innovations in food and agriculture. Acre's diverse portfolio includes notable investments in companies like Meati Foods, which specializes in clean, fungi-based protein meats and raised $50M in a Series B round co-led by Acre. Mori is another significant investment, providing silk-based coatings for food protection to reduce waste and extend shelf life. Inari, a unicorn company developing advanced seed breeding technology, is valued at $1.5B. Spoiler Alert is a B2B marketplace helping food businesses manage surplus food, thus reducing waste. Agrofy is an online platform for farm equipment and infrastructure products. Acre's investment strategy emphasizes sustainability and technological innovation in agrifood technology. Recently, Acre closed its third fund at $140 million, targeting advancements in agricultural robotics, AI, and machine learning. This includes investments in companies like Bonsai Robotics and Farm-ng, focusing on automation in agriculture. Leveraging extensive experience and strategic partnerships, including advisory roles from industry experts like Lynda Deakin from IDEO and Chef David Chang, Acre drives growth and innovation within its portfolio companies. The firm supports startups from pre-seed to Series B stages, ensuring they have the necessary resources and strategic guidance to succeed in the evolving agrifood tech sector.

Acrew Capital is a venture capital firm founded in 2019 and headquartered in Palo Alto, California. The firm focuses on investing in companies across various stages, from early to growth stages, emphasizing diversity and transformative technology. Acrew Capital operates two primary funds: the Long Term View (LTV) fund, which targets early-stage investments, and the Diversify Capital Fund (DCF), which focuses on growth-stage companies. The LTV fund invests in early-stage companies, typically in the Seed to Series A stages, with check sizes ranging from $1 to $15 million. The DCF fund is designed for growth-stage investments, offering $10 to $20 million per investment. Acrew Capital's investment strategy prioritizes deep domain expertise, diverse perspectives, and long-term commitments to their portfolio companies. The firm's core thesis areas include financial services, cybersecurity, data, augmented reality, virtual reality, web 3.0, and cryptocurrency sectors. Acrew Capital's notable investments include companies like Eden Health, BlockFi, and CipherTrace. They have successfully exited several investments through mergers and acquisitions, demonstrating a strong track record in identifying and nurturing high-potential startups​. The leadership team at Acrew Capital is composed of experienced professionals like Lauren Kolodny, Mark Kraynak, and Asad Khaliq, who bring extensive experience in venture capital and entrepreneurship. The firm's commitment to diversity is reflected in its team composition and investment approach, with a significant portion of its leadership being women or people of color​.

Act One Ventures, established in 2016 and based in Los Angeles, California, focuses on investing in early-stage companies, particularly in pre-seed and seed rounds. The firm primarily invests in sectors like e-commerce infrastructure, vertical SaaS, and fintech. Act One Ventures is known for its commitment to diversity, with over 70% of its portfolio companies led by women founders and those from underrepresented backgrounds. Notable investments by Act One Ventures include Cartwheel, a logistics and delivery software company; Dragonboat, a product portfolio management platform; Clovers, a human resources technology firm using conversational intelligence to enhance hiring practices; and Time Study, an AI-driven productivity tool for healthcare and enterprise applications. Act One Ventures takes a hands-on approach, working closely with founders to provide strategic guidance and support, helping startups navigate the challenges of early-stage growth. The firm's typical investment ranges from $500K to $3 million, reflecting its focus on providing substantial early support to its portfolio companies.

ACT Venture Capital, based in Dublin, Ireland, is an early-stage venture capital firm founded in 1994. The firm focuses on investing in high-potential technology companies across sectors such as AI, machine learning, enterprise software, deep tech, healthcare, and energy & climate. ACT has completed over 70 investments and manages around €627 million across multiple funds. Notable companies in ACT Venture Capital's portfolio include Cubic Telecom, a global connectivity management company; Ekco, a leading provider of cloud services; and Deciphex, which develops software solutions for digital pathology. The firm also backs companies like Gridbeyond, which focuses on intelligent energy management systems, and Provizio, an automotive safety technology company. ACT Venture Capital recently launched its sixth fund, ACT VI, with an initial close of €140 million, aiming to invest in 35 companies across its targeted sectors. This fund supports startups from seed to expansion stages, with the capacity to invest up to €10 million per company. The firm has a strong track record of successful exits, including the acquisition of SilverCloud Health by Amwell, Decawave by Qorvo, and Corvil by Pico. The leadership team at ACT includes John Flynn, Debbie Rennick, and John O’Sullivan, who bring extensive experience and expertise to the firm, supporting their portfolio companies through strategic guidance and robust networks.

ACT Venture Partners is an Amsterdam-based venture capital firm focusing on early-stage investments in deep-tech and enabling technologies across Europe, with additional strong ties to the Turkish market. They target sectors such as AI, IoT, data analytics, and healthcare, investing primarily during Seed and Series A rounds. ACT aims to back technically strong founders who are pioneering disruptive, market-transforming solutions. Some notable companies in their portfolio include Picus Security, Carbon Health, Eatron, and Nextmol. The firm typically leads seed rounds with checks up to €1 million, often continuing to support portfolio companies in subsequent funding rounds. Their investment strategy emphasizes hands-on collaboration, providing not only financial backing but also mentorship, networking, and strategic advice to help startups achieve critical product-market fit and scale. The core team comprises experienced professionals with backgrounds in engineering, finance, and entrepreneurship. Key figures include managing partners Erhan Kılıçözlü and Okan Kara, who bring decades of experience in tech transfer, venture capital, and innovation management, contributing to ACT's reputation as a value-adding partner for startups. ACT's approach involves close engagement from initial funding through to growth stages, leveraging their extensive network across Europe and beyond.

Action Potential Venture Capital (APVC) is a leading medical technology venture capital firm founded by GlaxoSmithKline (GSK) in 2013. The firm focuses on advancing bioelectronic medicines and enabling technologies. APVC is headquartered in Cambridge, Massachusetts, with additional offices in Scotts Valley, California. APVC invests in companies that leverage advances in hardware, computing, and material science to regulate neural or cellular activity, aiming to treat a range of chronic diseases. Notable portfolio companies include Cala Health, which develops non-invasive neuromodulation therapies for conditions like essential tremor; CVRx, known for its FDA-approved BAROSTIM NEO therapy for heart failure; and Neuspera Medical, which is developing minimally invasive neuromodulation therapies for overactive bladder. The firm takes a hands-on role on the boards of startups, providing strategic guidance and support. APVC has made 25 investments to date, with recent notable investments in Exo, which offers AI-enabled handheld ultrasound imaging, and MicroTransponder, which focuses on therapies for neurological conditions. APVC's investment approach emphasizes diversity and inclusion within the healthcare and entrepreneurial communities. The leadership team includes Imran Eba and Juan-Pablo Mas, who bring extensive experience in venture capital and biotechnology investments.

Activate Venture Partners, formerly known as Milestone Venture Partners, is an early-stage venture capital firm founded in 1999 and based in New York City. The firm focuses on investing in high-growth technology companies, particularly those in the healthcare and enterprise software sectors. Their strategy emphasizes being the first institutional investor in startups, with over 85% of their portfolio companies receiving pre-revenue investments​. Notable investments in their portfolio include companies like Healthify, Diameter Health, and Cureatr, reflecting their strong focus on healthcare technology. Additionally, they have invested in technology firms like Canvs.ai and Cloudnexa, which provide services ranging from market research to AWS management. Activate Venture Partners typically leads seed and early-stage financing rounds with initial investments often below $5 million. They are known for their hands-on approach, offering strategic guidance and support to help startups scale effectively. The leadership team includes co-founders Edwin Goodman and Todd Pietri, along with partners like Glen Bressner and Don Yount. Their extensive experience and deep industry connections provide valuable insights and resources to the companies they invest in​.

Acumen is a pioneering impact investment firm dedicated to addressing poverty through a unique approach it calls “patient capital,” designed to fund social enterprises that serve the most marginalized populations. Since its inception in 2001 by Jacqueline Novogratz, Acumen has invested over $150 million across 150+ companies worldwide. Its portfolio spans essential sectors like clean energy, agriculture, healthcare, and education, all aimed at empowering low-income communities with sustainable solutions that can operate at scale. Acumen’s methodology combines financial investment with a strong emphasis on management and leadership support. By focusing on long-term growth rather than immediate returns, Acumen supports businesses in emerging markets like East and West Africa, India, Latin America, and the U.S., ensuring they grow in both impact and profitability. Some of their prominent initiatives, such as off-grid energy projects in sub-Saharan Africa and affordable healthcare solutions in South Asia, reflect their commitment to transforming critical services for underserved populations. In addition to financial investment, Acumen fosters a culture of moral leadership through Acumen Academy, which educates entrepreneurs and social innovators on creating impactful and inclusive businesses. This dual approach of investment and training allows Acumen to build a pipeline of leaders and companies equipped to drive systemic change. With an extensive global network and partners ranging from corporate foundations to local entrepreneurs, Acumen continually expands its reach, working tirelessly to reimagine the role of capital in tackling poverty.